Cartesian Therapeutics P/B
The P/B (Price-to-Book Ratio) of Cartesian Therapeutics (RNAC) as of Oct 20, 2026 is -1.34. In the previous year, P/B (Price-to-Book Ratio) was -24.93 — a change of -94.61% (higher).
Get this data via API
Financial Data API
P/B
-1.34
YoY
-94.61%
Last updated:
The Cartesian Therapeutics P/B history
3 Years
10 Years
25 Years
Max
| YEAR | P/B | YoY |
|---|---|---|
| -1.34 | -94.61% | |
| -24.93 | +6,371.39% | |
| -0.39 | -121.32% | |
| 1.81 | -76.00% | |
| 7.53 | -179.95% | |
| -9.42 | -146.63% | |
| 20.19 | -164.52% | |
| -31.29 | -1,056.33% | |
| 3.27 | +6.07% | |
| 3.09 | -311.97% | |
| -1.46 | -24.67% | |
| -1.93 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cartesian Therapeutics Stock analysis
Frequently Asked Questions about Cartesian Therapeutics stock
P/B (Price-to-Book Ratio) of Cartesian Therapeutics is -1.34 in 2025.
P/B (Price-to-Book Ratio) of Cartesian Therapeutics changed from -24.93 to -1.34, representing a -94.61% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Cartesian Therapeutics since 2006 – with annual values, charts, and detailed analysis.
The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.
P/B = Stock Price / Book Value per Share
To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).
A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Cartesian Therapeutics with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Valuation — Cartesian Therapeutics
All Key Metrics — Cartesian Therapeutics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth